Sartorius BIA Separations and Exopharm Sign Joint Research Agreement

Published on: 

The agreement aims to develop integrated technology for large-scale exosome production.

Sartorius BIA Separations (BIA), a bio-chromatography company, and Exopharm, a company focused on medicines using exosomes, or extracellular vesicles, announced on Nov. 22, 2022 that they have entered into a formal collaboration. The companies have signed a Material Transfer Agreement that aims to use Exopharm’s patented LEAP technology alongside BIA’s Convective Interaction Media chromatography for improved large-scale therapeutic exosome production and commercialization.

According to a company press release, exosomes have advantages over alternative nanoparticle delivery technologies, as they are non-toxic, efficient at delivering RNA cargoes into cells, and able to do so without eliciting an immune response. Exosomes can also be engineered to provide specific delivery as well as repeated dosing.

“BIA sees the potential in exosomes for new and innovative therapeutic applications and understands that purification of exosomes has held back their adoption as a non-viral drug-delivery technology,” said Aleš Strancar, co-founder and managing director of BIA, in the release. “We believe that BIA’s CIM monolith technology and Exopharm’s exosome-specific LEAP ligands can work synergistically together to enhance specificity, efficiency and capacity of industrial exosome purification processes. This work with Exopharm has the potential to be a game-changer in the emerging exosome field.”


Source: Sartorius BIA Separations